292 related articles for article (PubMed ID: 10648422)
1. Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.
Pilarski LM; Hipperson G; Seeberger K; Pruski E; Coupland RW; Belch AR
Blood; 2000 Feb; 95(3):1056-65. PubMed ID: 10648422
[TBL] [Abstract][Full Text] [Related]
2. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors.
Pilarski LM; Belch AR
Clin Cancer Res; 2002 Oct; 8(10):3198-204. PubMed ID: 12374689
[TBL] [Abstract][Full Text] [Related]
3. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
4. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction.
Szczepek AJ; Seeberger K; Wizniak J; Mant MJ; Belch AR; Pilarski LM
Blood; 1998 Oct; 92(8):2844-55. PubMed ID: 9763569
[TBL] [Abstract][Full Text] [Related]
5. Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells.
van der Loo JC; Hanenberg H; Cooper RJ; Luo FY; Lazaridis EN; Williams DA
Blood; 1998 Oct; 92(7):2556-70. PubMed ID: 9746798
[TBL] [Abstract][Full Text] [Related]
6. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.
Pilarski LM; Seeberger K; Coupland RW; Eshpeter A; Keats JJ; Taylor BJ; Belch AR
Exp Hematol; 2002 Mar; 30(3):221-8. PubMed ID: 11882359
[TBL] [Abstract][Full Text] [Related]
7. Identification of human juvenile chronic myelogenous leukemia stem cells capable of initiating the disease in primary and secondary SCID mice.
Lapidot T; Grunberger T; Vormoor J; Estrov Z; Kollet O; Bunin N; Zaizov R; Williams DE; Freedman MH
Blood; 1996 Oct; 88(7):2655-64. PubMed ID: 8839860
[TBL] [Abstract][Full Text] [Related]
8. Multilineage engraftment in NOD/LtSz-scid/scid mice from mobilized human CD34+ peripheral blood progenitor cells.
Hogan CJ; Shpall EJ; McNiece I; Keller G
Biol Blood Marrow Transplant; 1997 Nov; 3(5):236-46. PubMed ID: 9450918
[TBL] [Abstract][Full Text] [Related]
9. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors.
Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE
Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634
[TBL] [Abstract][Full Text] [Related]
10. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
[TBL] [Abstract][Full Text] [Related]
11. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor.
Gazitt Y; Tian E; Barlogie B; Reading CL; Vesole DH; Jagannath S; Schnell J; Hoffman R; Tricot G
Blood; 1996 Jan; 87(2):805-11. PubMed ID: 8555506
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow versus peripheral blood progenitor cells CD34 selection in patients with non-Hodgkin's lymphomas: different levels of tumor cell reduction. Implications for autografting.
Lopez M; Lemoine FM; Firat H; Fouillard L; Laporte JP; Lesage S; Isnard F; Stachowiak J; Ferrer-Le Coeur F; Morel P; Najman A; Douay L; Gorin NC
Blood; 1997 Oct; 90(7):2830-8. PubMed ID: 9326252
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
[TBL] [Abstract][Full Text] [Related]
14. Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone.
Reiman T; Seeberger K; Taylor BJ; Szczepek AJ; Hanson J; Mant MJ; Coupland RW; Belch AR; Pilarski LM
Blood; 2001 Nov; 98(9):2791-9. PubMed ID: 11675353
[TBL] [Abstract][Full Text] [Related]
15. Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor.
Neben S; Marcus K; Mauch P
Blood; 1993 Apr; 81(7):1960-7. PubMed ID: 7681707
[TBL] [Abstract][Full Text] [Related]
16. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources.
Léonard BM; Hétu F; Busque L; Gyger M; Bélanger R; Perreault C; Roy DC
Blood; 1998 Jan; 91(1):331-9. PubMed ID: 9414302
[TBL] [Abstract][Full Text] [Related]
17. A negative-selection strategy for depleting myeloma cells from patients' BM and/or leukapheresis blood.
Louis SA; Zapf R; Clarke E; Thomas TE; Sutherland HJ
Cytotherapy; 2001; 3(6):489-504. PubMed ID: 11953033
[TBL] [Abstract][Full Text] [Related]
18. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.
Vescio RA; Han EJ; Schiller GJ; Lee JC; Wu CH; Cao J; Shin J; Kim A; Lichtenstein AK; Berenson JR
Bone Marrow Transplant; 1996 Jul; 18(1):103-10. PubMed ID: 8832002
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy.
Fruehauf S; Haas R; Conradt C; Murea S; Witt B; Möhle R; Hunstein W
Blood; 1995 May; 85(9):2619-26. PubMed ID: 7537123
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood.
Murray L; Chen B; Galy A; Chen S; Tushinski R; Uchida N; Negrin R; Tricot G; Jagannath S; Vesole D
Blood; 1995 Jan; 85(2):368-78. PubMed ID: 7529060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
